Medical News

RSS

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE Mark for AdVance XP. The device is the latest generation of AMS' AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI).

9 Aug 2010

Dr Reddy’s launches first generic darbepoetin alfa

Dr. Reddy's Laboratories Ltd. announced today the launch of Cresp® - the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India. Cresp® has been approved in India for the treatment of anemia due to chronic kidney disease and anemia due to chemotherapy.

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

CryoPatch SG pulmonary human cardiac patch receives FDA clearance for 5-year shelf-life extension

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.

9 Aug 2010

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

CPEX Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. For the quarter CPEX reported revenues of $5.8 million and net income of $1.2 million.

9 Aug 2010

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Roche announced today that after priority review, Health Canada has approved HERCEPTIN(R) (trastuzumab), in combination with XELODA(R) (capecitabine) or intravenous 5-fluorouracil and cisplatin, for the first-line treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach (gastric cancer) or gastro-esophageal cancer.

9 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Sparton Medical Systems acquires Delphi Medical's contract manufacturing business assets

Sparton Corporation, a supplier of complex and reliable electronic and electro-mechanical products, sub-assemblies and related services to the highly regulated Medical, Defense & Security, and Aerospace markets announces that on August 6, 2010 its wholly owned subsidiary, Sparton Medical Systems Colorado, LLC, completed its previously announced acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC. The all-cash transaction is valued at approximately $8.0 million.

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

Arcadia Resources first-quarter net revenues decrease to $25.8 million

Arcadia Resources, Inc., a leading provider of innovative consumer health care services under the Arcadia HealthCare(SM) brand, today announced fiscal 2011 first quarter net revenues of $25.8 million and a net loss of $4.0 million, or $0.02 per share, which compares to net revenue of $26.4 million and a net loss of $4.6 million, or $0.03 per share for the same period in the fiscal 2010.

9 Aug 2010

Vanguard to acquire assets of Arizona Heart Hospital

MedCath Corporation, and its physician partners jointly announced today they have entered into a definitive agreement for Vanguard Health Systems to acquire substantially all the assets of Arizona Heart Hospital. The transaction is expected to close during MedCath's first quarter of fiscal 2011, which ends on December 31, 2010, subject to certain closing conditions.

9 Aug 2010

Amedisys second-quarter net service revenue increases 11.8% to $422.3 million

Amedisys, Inc., one of America's leading home health nursing companies, today reported its financial results for the three and six-month periods ended June 30, 2010. Net service revenue increased 11.8% while net income attributable to Amedisys, Inc., decreased 8.2% over the three-month period ended June 30, 2009.

9 Aug 2010

Lowell PHO implements MedVentive's technology to manage risk, quality performance

Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.

9 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

Medical Action Industries first-quarter fiscal 2011 net sales decrease 5.5%

Medical Action Industries Inc., a leading supplier of medical and surgical disposable products, today reported fiscal results for the first quarter ended June 30, 2010.

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Millennium Laboratories, Inc., a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced today a national agreement with MultiPlan, the nation's leading comprehensive provider of healthcare cost management solutions. As a participating provider in the PHCS and MultiPlan Networks, Millennium Laboratories will assist participating physicians with state-of-the-art therapeutic drug monitoring services and tools.

9 Aug 2010

Medical News

Progenics second-quarter total revenue decreases to $2.3 million

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

Dr Reddy’s launches first generic darbepoetin alfa

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CryoPatch SG pulmonary human cardiac patch receives FDA clearance for 5-year shelf-life extension

CPEX reports $1.2M second-quarter net income vs $1.2M net loss year earlier

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Sparton Medical Systems acquires Delphi Medical's contract manufacturing business assets

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Arcadia Resources first-quarter net revenues decrease to $25.8 million

Vanguard to acquire assets of Arizona Heart Hospital

Amedisys second-quarter net service revenue increases 11.8% to $422.3 million

Lowell PHO implements MedVentive's technology to manage risk, quality performance

BioVentrix announces First-in-Man milestone for PliCath heart failure system

Medical Action Industries first-quarter fiscal 2011 net sales decrease 5.5%

GTx second-quarter net loss increases to $12.9 million

Millennium Laboratories signs agreement to assist physicians with drug monitoring services, tools

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News